image

The best stocks to buy since 1993

Latest issue now available

SIGN UP NOW
Updates

Bespak - Customer Pfizer close to Exubera filing

May 2002

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • BPK
Bespak held a technology workshop for analysts over the month which delivered two key messages. Firstly, that Bespak's developments in metered dose valves are on the point of generating revenues and, secondly, that the development of its nasal drug delivery is progressing well and that the project could be validated within two or three years.      Bespak has also announcedtwo research collaborations. One is with medical device company, DEKAResearch and Development, to develop new pulmonary drug deliverydevices and the other is with CIIT Centers for Health Research todevelop nasal drug delivery devices. Whenwe made the shares a Buy in February, we reckoned Pfizer would f ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Related Articles

Bespak - Pfizer's Exubera to excite shares (February 2002)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

LIMITED PERIOD OFFER

SUBSCRIBE TODAY AND SAVE £40 WITH OFFER CODE 40OFFSCSW

To access our archive of articles and to receive current issues you need to subscribe

SUBSCRIBE NOW